Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Anna Asklid"'
Autor:
Maria Winqvist, Per-Ola Andersson, Anna Asklid, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Richard Rosenquist, Florentin Späth, Lotta Hansson, Anders Österborg, for the Swedish CLL Group
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
Externí odkaz:
https://doaj.org/article/557cf31a3b0c443e9a21307f6fba6401
Autor:
Sandra Eketorp Sylvan, Anna Asklid, Hemming Johansson, Jenny Klintman, Jenny Bjellvi, Staffan Tolvgård, Eva Kimby, Stefan Norin, Per-Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Bergendahl Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson
Publikováno v:
Haematologica, Vol 104, Iss 4 (2019)
The aim of this study was to investigate long-term outcome following first-line therapy in consecutive chronic lymphocytic leukemia (CLL) patients in a well-defined geographic area: Sweden. All patients diagnosed with CLL (2007–2013) (n=3672) were
Externí odkaz:
https://doaj.org/article/f8ee6428d9824583bdf7bcb653686120
Autor:
Maria Winqvist, Anna Asklid, PO Andersson, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Österborg
Publikováno v:
Haematologica, Vol 101, Iss 12 (2016)
Ibrutinib, a Bruton’s tyrosine kinase inhibitor is approved for relapsed/refractory and del(17p)/TP53 mutated chronic lymphocytic leukemia. Discrepancies between clinical trials and routine health-care are commonly observed in oncology. Herein we r
Externí odkaz:
https://doaj.org/article/17844351e93d48cba09381bafdfe16c8
Autor:
Maria Winqvist, Lotta Hansson, Anders Österborg, Sandra Eketorp Sylvan, Richard Rosenquist, Jeanette Lundin, Anna Asklid, Agnes Mattsson, Larry Mansouri, Joel Wiggh, Hemming Johansson
Publikováno v:
British Journal of Haematology
Summary Bendamustine + rituximab (BR) is the current first‐line standard‐of‐care for chronic lymphocytic leukaemia (CLL) in fit patients aged 66–70 years, whereas chlorambucil + CD20 antibody is recommended in older patients with co‐morbidi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3538b230c4457c2756bd0ba4332e3cc
https://pubmed.ncbi.nlm.nih.gov/32761826
https://pubmed.ncbi.nlm.nih.gov/32761826
Autor:
Anna Asklid, Maria Winqvist, Lotta Hansson, Agnes Mattsson, Sandra Eketorp Sylvan, Anders Österborg, Hemming Johansson
Publikováno v:
Leukemialymphoma. 61(9)
This real-world study investigated outcome of first-line treatment in elderly patients with diffuse large B-cell lymphoma (DLBCL). All (n = 292) new DLBCL patients ≥80 years diagnosed in the Stockh...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a499a581094f595bab1986514849ae
https://pubmed.ncbi.nlm.nih.gov/32449636
https://pubmed.ncbi.nlm.nih.gov/32449636
Autor:
Per-Ola Andersson, Karin Karlsson, Claes Karlsson, Florentin Späth, Richard Rosenquist, Birgitta Lauri, Mattias Mattsson, Jeanette Lundin, Anders Österborg, Lotta Hansson, Stefan Norin, Anna Asklid, Anna Sandstedt, Maria Winqvist
Publikováno v:
Haematologica. 104:e208-e210
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia : 30-month follow up of the Swedish compassionate use cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4bcb5ac6215d262c7876897d810b9a
https://doi.org/10.3324/haematol.2018.198820
https://doi.org/10.3324/haematol.2018.198820
Autor:
Ulrich Jäger, Frans Søltoft, Anders Österborg, Sandra Eketorp-Sylvan, Johanna Repits, Joris Diels, Lotta Hansson, Anna Asklid
Publikováno v:
Annals of Hematology
This study explored the relative efficacy of ibrutinib versus previous standard-of-care treatments in relapsed/refractory patients with chronic lymphocytic leukaemia (CLL), using multivariate regression modelling to adjust for baseline prognostic fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d276cb40429cdf94c986a4610ea34650
http://europepmc.org/articles/PMC5569664
http://europepmc.org/articles/PMC5569664
Autor:
Lotta Hansson, Johanna Repits, Frans Søltoft, Sandra Eketorp Sylvan, Anna Asklid, Anders Österborg, Joris Diels, Maria Winqvist, Agnes Mattsson, Einar Björgvinsson
Publikováno v:
Leukemia & Lymphoma. 58:1219-1223
Real-world data is important for comparison when new orphan drugs are evaluated in non-controlled phase 2 trials in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). The S...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8be7c87daf6c3fa1497b87c27d8fd1
https://doi.org/10.1080/10428194.2016.1246727
https://doi.org/10.1080/10428194.2016.1246727
Autor:
Jenny Klintman, Stefan Norin, Mattias Mattsson, Sandra Eketorp Sylvan, Eva Kimby, Per-Ola Andersson, Maria Strandberg, Birgitta Lauri, Hemming Johansson, Anna Sandstedt, Anna Asklid, Claes Karlsson, Staffan Tolvgård, Jenny Bjellvi, Lotta Hansson, Anders Österborg, Karin Karlsson
Publikováno v:
Haematologica
The aim of this study was to investigate long-term outcome following first-line therapy in consecutive chronic lymphocytic leukemia (CLL) patients in a well-defined geographic area: Sweden. All patients diagnosed with CLL (2007-2013) (n=3672) were id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ece5bf959495d889135c22d921a9edca
https://pubmed.ncbi.nlm.nih.gov/30467205
https://pubmed.ncbi.nlm.nih.gov/30467205
Autor:
Agnes Mattsson, Maria Winqvist, Anna Asklid, Sandra Eketorp Sylvan, Joris Diels, Frans Söltoft, Johanna Repits, Einar Björgvinsson, Lotta Hansson, Anders Österborg
Publikováno v:
Blood. 126:4166-4166
Background: Treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) remains challenging. Major progress has been achieved with new agents such as ibrutinib and idelalisib. However relapses still occur with these agents or the tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a08b8365e624e6680ce52a36e3e95408
https://doi.org/10.1182/blood.v126.23.4166.4166
https://doi.org/10.1182/blood.v126.23.4166.4166